These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30343954)

  • 1. Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.
    Rana S; Sonawane YA; Taylor MA; Kizhake S; Zahid M; Natarajan A
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3736-3740. PubMed ID: 30343954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.
    Kour S; Rana S; Contreras JI; King HM; Robb CM; Sonawane YA; Bendjennat M; Crawford AJ; Barger CJ; Kizhake S; Luo X; Hollingsworth MA; Natarajan A
    Mol Pharmacol; 2019 Oct; 96(4):419-429. PubMed ID: 31467029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor.
    Opoku-Temeng C; Dayal N; Hernandez DE; Naganna N; Sintim HO
    Chem Commun (Camb); 2018 May; 54(36):4521-4524. PubMed ID: 29629444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
    Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B
    Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
    King HM; Rana S; Kubica SP; Mallareddy JR; Kizhake S; Ezell EL; Zahid M; Naldrett MJ; Alvarez S; Law HC; Woods NT; Natarajan A
    Bioorg Med Chem Lett; 2021 Jul; 43():128061. PubMed ID: 33895280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R
    Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
    El-Naggar AM; El-Hashash MA; Elkaeed EB
    Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
    Jing L; Tang Y; Xiao Z
    Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical synthesis of the major 3-hydroxy-2-pyrrolidinone metabolite of a potent CDK2/cyclin A inhibitor.
    Nesi M; Borghi D; Brasca MG; Fiorentini F; Pevarello P
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3205-8. PubMed ID: 16616492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazolobenzodiazepines: part I. Synthesis and SAR of a potent class of kinase inhibitors.
    Liu JJ; Daniewski I; Ding Q; Higgins B; Ju G; Kolinsky K; Konzelmann F; Lukacs C; Pizzolato G; Rossman P; Swain A; Thakkar K; Wei CC; Miklowski D; Yang H; Yin X; Wovkulich PM
    Bioorg Med Chem Lett; 2010 Oct; 20(20):5984-7. PubMed ID: 20832307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
    Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
    Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrimidine-based pyrazoles as cyclin-dependent kinase 2 inhibitors: Design, synthesis, and biological evaluation.
    Vekariya MK; Vekariya RH; Brahmkshatriya PS; Shah NK
    Chem Biol Drug Des; 2018 Sep; 92(3):1683-1691. PubMed ID: 29767460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
    Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
    Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
    Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
    Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in Pyrazole Based Scaffold as Cyclin-dependent Kinase 2 Inhibitors for the Treatment of Cancer.
    Shaikh J; Patel K; Khan T
    Mini Rev Med Chem; 2022; 22(8):1197-1215. PubMed ID: 34711160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.
    Hu X; Zhao H; Wang Y; Liu Z; Feng B; Tang C
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3385-3390. PubMed ID: 30197029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.
    Jansa J; Jorda R; Škerlová J; Pachl P; Peřina M; Řezníčková E; Heger T; Gucký T; Řezáčová P; Lyčka A; Kryštof V
    Eur J Med Chem; 2021 Apr; 216():113309. PubMed ID: 33711765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.